The effects of co-targeting pathways on viral distribution in NB + 12 SMGs. In control SMGs (A), uninfected epithelia and stroma appear pink. In mCMV-infected SMGs (B), densely-packed β-galactosidase-stained virus is seen thoughout stroma and in epithelial duct cells. In GEF-treated, mCMV-infected SMGs treated with U0126 beginning on day 6 (C), there is a reduction in β-galactosidase-stained virus in stroma and a more notable reduction in epithelia compared to untreated SMGs (compare C to B). In U0126-treated, mCMV-infected SMGs treated with GEF beginning on day 6 (D), there is a greater reduction in β-galactosidase-stained virus than seen in SMGs initially treated with GEF (compare D to C). Addition of aciclovir beginning on day 6 to GEF-treated, mCMV-infected SMGs (E) and U0126-treated, mCMV-infected SMGs (F) results in the near absense of β-galactosidase-stained virus. Bar: A-C, E-F, 50 μm; D 60 μm.